Search results for "Systolic hypertension"

showing 9 items of 9 documents

OASIS-HT: design of a pharmacogenomic dose-finding study.

2005

Experimental evidence and observations in humans strongly support an interactive role of mutated α-adducin, sodium (Na+)/potassium (K+)-adenosine triphosphatase (ATPase) activity and endogenous ouabain in Na+homeostasis and the pathogenesis of hypertension. The Ouabain and Adducin for Specific Intervention on Sodium in HyperTension (OASIS-HT) trial is an early Phase II dose-finding study, which will be conducted across 39 European centers. Following a run-in period of 4 weeks without treatment, eligible patients will be randomized to one of five oral doses of rostafuroxin consisting of 0.05, 0.15, 0.5, 1.5, or 5.0 mg/day. Each dose will be compared to a placebo in a double-blind crossover e…

AdultMalemedicine.medical_specialtyRandomizationTime FactorsSystolic hypertensionMolecular ConformationAdministration OralBlood PressurePharmacologyPlaceboOuabainDrug Administration ScheduleDouble-Blind MethodRisk FactorsInternal medicineGeneticsClinical endpointMedicineHumansAndrostanolsOuabainAntihypertensive AgentsPharmacologyCross-Over StudiesDose-Response Relationship Drugbusiness.industryMiddle Agedmedicine.diseaseCrossover studyBlood pressureEndocrinologyTreatment OutcomeHypertensionMolecular MedicineCalmodulin-Binding ProteinsFemalebusinessHomeostasismedicine.drugPharmacogenomics
researchProduct

Isolated Systolic Hypertension in the Young

2019

Elevated systolic blood pressure with normal diastolic blood pressure is the most prevalent type of hypertension in young people. The prevalence of isolated systolic hypertension reported among youth ranges widely as a result of the differences in population characteristics such as age, ethnicity, and obesity. Even though it is not an unusual condition, there is still debate in the literature about the clinical significance of an isolated increase in systolic blood pressure detected in the first decades of life. The reported phenotypic characteristics of subjects with isolated systolic hypertension are rather scarce and many relevant pieces of information are still elusive. Further studies …

Benign conditionmedicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationmedicine.diseaseObesityBlood pressureElevated systolic blood pressureInternal medicineNormal diastolic blood pressureIsolated systolic hypertensionmedicineCardiologyClinical significanceeducationbusiness
researchProduct

Effects of Nifedipine on Blood Pressure, Arterial Compliance and Left Ventricular Mass in Elderly Patients with Isolated Systolic Hypertension

1989

The aim of this study was to evaluate the effects of acute and chronic administration of slow-release nifedipine (SRN) on blood pressure (BP), aortic index (AI), average wall stress (AWS), left ventricular mass (LVM), and other hemodynamic parameters in elderly patients with isolated systolic hypertension (ISH) (systolic blood pressure [SBP] > 175 mmHg). We studied 10 patients (mean age 73.7 ± 5.6 years) in which after a washout period, in basal conditions, 3 h after the administration of SRN (20 mg), and 180 days after chronic therapy (40 mg daily), we evaluated the changes of BP, HR, AI, AWS, LVM, and other parameters obtained by means of echocardiography. After SRN we observed a signific…

DiminutionSupine positionbusiness.industrySystolic hypertensionHemodynamicsmedicine.diseasemedicine.anatomical_structureBlood pressureNifedipineVentricleAnesthesiamedicineVascular resistancebusinessmedicine.drug
researchProduct

Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension

2000

To investigate the efficacy and tolerability of lercanidipine, used as monotherapy once a day, in elderly patients with isolated systolic hypertension (ISH), 83 patients were enrolled in this multicenter, double-blind, randomized, placebo-controlled study. All patients were older than 60 years, and their mean age was 66.7 +/- 5.4 years. ISH was defined as SBPor = 160 mmHg, and DBP95 mmHg. After wash-out and placebo run-in periods, patients were randomly assigned to placebo or lercanidipine (10 mg once a day) treatment for 4 weeks. Non-responding patients of the lercanidipine-treated group were later treated with 20 mg of lercanidipine once a day for 4 additional weeks. At the end of the stu…

MaleAgingDihydropyridinesSystoleBlood PressurePlaceboPlacebo groupOrthostatic vital signsDouble-Blind MethodDiastoleHeart ratemedicineHumansAntihypertensive AgentsAgedbusiness.industryLercanidipineMiddle AgedBlood pressureTreatment OutcomeTolerabilityAnesthesiaIsolated systolic hypertensionHypertensionFemaleGeriatrics and Gerontologybusinessmedicine.drug
researchProduct

Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST tria…

2010

Introduction: Systolic hypertension is very common in the elderly and is strongly associated with the risk of cardiovascular and cerebrovascular events. The control of systolic hypertension is difficult and most patients require combination antihypertensive therapy. Few data are available regarding the efficacy of angiotensin II receptor antagonists on systolic hypertension of the elderly. The aim of this double-blind, double-dummy, randomized, parallel-group, multicenter study was to assess the efficacy of eprosartan 600 mg in combination with hydrochlorothiazide (HCTZ)12.5 mg in comparison with losartan 50 mg in combination with HCTZ 12.5 mg, in reducing blood pressure in elderly patients…

MaleSystolic hypertensionOffice VisitsPharmacologySeverity of Illness Indexlaw.inventionHydrochlorothiazideRandomized controlled triallawAngiotensin II Type 1 Receptor BlockerPharmacology (medical)DiureticsImidazolesGeneral MedicineBlood Pressure Monitoring AmbulatoryAntihypertensive AgentLosartanHydrochlorothiazideTreatment OutcomeAcrylatesHypertensionCardiologyDrug Therapy CombinationFemaleDrug MonitoringHumanmedicine.drugmedicine.medical_specialtyAmbulatory blood pressureSystoleLosartan/hydrochlorothiazideThiopheneselderly patientselderlyLosartanStatistics NonparametricDouble-Blind MethodThiopheneInternal medicinemedicineDiureticHumansImidazoleAntihypertensive AgentsAgedAnalysis of Variancebusiness.industryeprosartanEprosartanmedicine.diseaseambulatory blood pressure monitoringAcrylateBlood pressureOffice VisitbusinessAngiotensin II Type 1 Receptor BlockersAdvances in therapy
researchProduct

Effectiveness and Tolerability of Fixed-Dose Combination Enalapril plus Nitrendipine in Hypertensive Patients Results of the 3-Month Observational, P…

2009

Background and objective: Monotherapy with any class of antihypertensive drug effectively controls blood pressure (BP) in only about 50% of patients. Consequently, the majority of patients with hypertension require combined therapy with two or more medications. This study aimed to evaluate the effectiveness (systolic BP [SBP]/diastolic BP [DBP] control) and tolerability of the fixed-dose combination enalapril/nitrendipine 10 mg/20 mg administered as a single daily dose in hypertensive patients. Methods: This was a post-authorization, multicentre, prospective, observational study conducted in primary care with a 3-month follow-up. Patients throughout Spain with uncontrolled hypertension (>= …

Malemedicine.medical_specialtymedicine.drug_classSystolic hypertensionFixed-dose combinationPopulationAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionEnalaprilInternal medicinemedicineProduct Surveillance PostmarketingHumansPharmacology (medical)EnalaprilProspective StudieseducationAntihypertensive drugAntihypertensive Agentseducation.field_of_studyDose-Response Relationship DrugPrimary Health Carebusiness.industryNitrendipineGeneral MedicineMiddle Agedmedicine.diseaseCalcium Channel BlockersDrug CombinationsBlood pressureTolerabilityAnesthesiaHypertensionFemalebusinessmedicine.drug
researchProduct

Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets

2016

Abstract The European Society of Hypertension recommend the following main rules for treatment of hypertension in elderly and octogenarians: 1) In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 140 mmHg and 150 mmHg. 2) In fit elderly patients less than 80 years old treatment may be considered at SBP ≥ 140 mmHg with a target SBP < 140 mmHg if treatment is well tolerated. 3) In fit individuals older than 80 years with an initial SBP ≥ 160 mmHg it is recommended to reduce SBP to between 150 mmHg and 140 mmHg. 4) In frail elderly patients, it is recommended to base treatment decisions on comorbidity and carefully monitor the effects of tr…

medicine.medical_specialtyBlood Pressure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicinemedicineHumansFrail elderly030212 general & internal medicineIntensive care medicineBlood pressure-lowering treatmentAgedAged 80 and overoctogenarianbusiness.industryGeneral Medicineblood pressure targetmedicine.diseaseComorbidityelderly patientEuropeBlood pressureEuropean Society of HypertensionHypertensionIsolated systolic hypertensionTreatment decision makingCardiology and Cardiovascular MedicinebusinessBlood Pressure
researchProduct

Morbidity and mortality on combination versus monotherapy in the Systolic Hypertension in Europe Trial

2009

medicine.medical_specialtySystolic hypertensionbusiness.industryEmergency medicinemedicineCardiology and Cardiovascular Medicinemedicine.diseaseIntensive care medicinebusinessInternational Journal of Cardiology
researchProduct

Chronic Administration of Slow-Release Nifedipine Improves Arterial Compliance in Elderly Hypertensives with Systolic Hypertension

1988

medicine.medical_specialtySystolic hypertensionbusiness.industryGeneral Neurosciencemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyCompliance (physiology)History and Philosophy of ScienceNifedipineInternal medicinemedicineCardiologybusinessAdministration (government)medicine.drugAnnals of the New York Academy of Sciences
researchProduct